oxane

We are oxane CAS:142-68-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   oxane
CAS.NO: 142-68-7
Molecular Formula: C5H10O
Molecular Weight: 86.13230

Synonyms:
Tetrahydropyran
2H-Pyran, tetrahydro-
Tetarhydropyran
Tetrahydro-2H-pyran
Etrahydropyran
4,5-dihydro-2H-pyran
1,5-EPOXYPENTANE
tetrahydro-4H-pyran
OXACYCLOHEXANE
tetrahydropyrane
THP
4-tetrahydropyran
tetrahydro-2h-pyra
Pentamethylene Oxide

Physical and Chemical Properties:
Density: 0.881 g / mL at 25 ° C (lit.)
Boiling point: 88 ° C (lit.)
Melting point: −45 ° C (lit.)
Flash point: 4 ° F
Refractive index: n20 / D 1.42 (lit.)

Specification:
Appearance: Colorless Liquid
Purity:≥99.0%
Water: 0.2% max
Dihydropyran: 1.0% max

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:The storeroom is ventilated and dry at low temperature, and it is not easy to store for a long time to prevent the generation of peroxides.
Application:  
Tetrahydropyran is a useful synthetic intermediate. Tetrahydropyranyl (THP-) ethers derived from the reaction of alcohols and dihydropyran are common intermediates in organic synthesis. In organic synthesis, the 2-tetrahydropyranyl group is used as a protecting group for alcohols.

Related News: That impacts airlines’ business, making it less financially attractive for them to fly those routes to China.214470-66-3 That impacts airlines’ business, making it less financially attractive for them to fly those routes to China.1-(Mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole CAS:74257-00-4 This part is mainly anti-tumor drugs, prostate drugs and certain hormone drugs.5-bromo-2-chloro-4’-ethoxydiphenylmethane CAS:461432-23-5 This part is mainly anti-tumor drugs, prostate drugs and certain hormone drugs.Jo Soden, Co-managing Director of Retrogenix, said “We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant’s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.”